COMP <GO>
SPXC vs TMO // EV/EBITDA & P/E VALUATION
SPX Technologies Inc. (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: SPXC 7
— TMO 8
▲ EV/EBITDA & P/E VALUATION LEADER: SPXC
LAST: $159.95 (-4.37%) • MKT CAP: $8.38B
valuation
20.0x
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
valuation
30.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SPXC VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SPXC | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 40.50% | 41.00% | -0.50 | TMO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 10.60% | 9.30% | +1.30 | SPXC | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 20.0x | 30.4x | -10.40 | SPXC | /valuation <GO> |
| Free Cash Flow Yield | 2.76% | 2.40% | +0.36 | SPXC | /fcf-yield <GO> |
| Operating Margin | 15.50% | 17.40% | -1.90 | TMO | /operating-margins <GO> |
| Net Profit Margin | 10.80% | 15.10% | -4.30 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 14.20% | 3.90% | +10.30 | SPXC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.27 | 4.50 | -0.23 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | SPXC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 6.70% | +0.10 | TMO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 36.3 | 59.1 | -22.86 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.96 | 0.94 | +0.02 | SPXC | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.8x | 36.3x | -7.50 | SPXC | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $8.38B | $262.22B | -$253.84B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SPXC REV | TMO REV | SPXC GROSS % | TMO GROSS % | SPXC FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.27B | $44.56B | 40.5% | 44.0% | $231.4M | $6.29B |
| FY 2024 | $1.98B | $42.88B | 40.3% | 44.0% | $196.6M | $7.27B |
| FY 2023 | $1.74B | $42.86B | 44.0% | 44.0% | $130.1M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SPXC // BETA 0.96
TMO // BETA 0.94